A New Kind of Diabetes Monitor Gets FDA Authorization
The U.S. Food and Drug Administration has authorized what it describes as the first wearable sensor that continuously tracks both ketones and blood sugar at the same time, marking a notable expansion in how diabetes-related risks can be monitored outside clinics and hospitals. The device, Abbott’s Libre Duo 10 Day, is intended to give patients and caregivers earlier warning when ketone levels begin to rise, potentially signaling the onset of diabetic ketoacidosis, or DKA.
The authorization matters because ketones and glucose are linked but not interchangeable measurements. Glucose monitoring has become routine for many people with diabetes, especially those using continuous glucose monitors. Ketone monitoring, by contrast, has usually required separate blood or urine tests that are performed only when symptoms appear or when a person already suspects something is wrong. That gap can be consequential, because DKA can escalate quickly and early symptoms may be mistaken for a minor illness.
Why Ketones Matter
Ketones are chemicals the body produces when it burns fat instead of sugar for fuel. In people with diabetes, especially those who depend on insulin, elevated ketones can indicate that the body is not getting enough usable insulin. If ketone levels continue to climb, DKA can develop. The condition is a medical emergency associated with dehydration, dangerous blood chemistry changes, and in severe cases coma or death.
According to the source material, the American Diabetes Association warns that DKA can worsen within hours if untreated. That time pressure is one reason continuous ketone monitoring could change patient behavior. Instead of relying on a single test after symptoms appear, a wearable device can show whether ketones are stable, rising, or moving into a concerning range.
The FDA underscored that point in its authorization announcement. Dr. Michelle Tarver, director of the FDA’s Center for Devices and Radiological Health, said real-time ketone information can make the difference between early intervention and a life-threatening emergency. That framing suggests the agency sees the device as more than a convenience feature. It is being positioned as a tool for earlier detection of an acute complication that often develops faster than patients expect.
How the Device Works
The Libre Duo 10 Day is a skin-worn sensor that reads both glucose and ketones in interstitial fluid, the fluid just beneath the skin. The source text says the sensor measures both values every minute, day and night, and sends the readings wirelessly to a smartphone app. The app displays current values, shows directional trends, and issues an alert when ketones reach a concerning level.
That combined approach is the device’s main technical distinction. Until now, continuous monitoring has largely centered on glucose alone, while ketone checks remained episodic. By placing both data streams into a single wearable, Abbott is effectively trying to extend the continuous-monitoring model from day-to-day glucose management into acute-risk surveillance.
The product is authorized for people with diabetes age 2 and older. Abbott says it is aimed particularly at users who face higher risk of elevated ketones, including people who take insulin or glucose-lowering medications. The source text also notes that six studies involving more than 60 participants supported the device, though the candidate text provided does not include fuller details on study design or comparative performance.
A Response to a Growing Clinical Problem
The authorization arrives against a backdrop of rising DKA admissions. The supplied source text says Abbott cited a 55% increase in hospital admissions for DKA over the past decade. Even if some of that increase reflects broader changes in diabetes diagnosis, treatment patterns, or access to care, the trend helps explain why regulators and device makers are paying closer attention to ketone monitoring.
One problem is that many patients do not keep a blood ketone meter at home. Another is that symptoms such as nausea, stomach pain, or general malaise can be misread as a stomach virus or another common infection. In practice, that means a patient may continue normal routines while a dangerous metabolic shift is already underway. A continuous sensor cannot eliminate that risk, but it may shorten the time between biochemical change and practical response.
For pediatric care, that could be especially meaningful. Young children may struggle to describe symptoms clearly, and caregivers often have to interpret vague signs of illness. A paired glucose-ketone wearable could make it easier to distinguish routine fluctuations from warning signals that deserve faster medical attention.
What This Means for the Device Market
The FDA decision also points to a broader shift in the wearable health market. Continuous sensors have expanded from niche medical tools into a fast-moving category that sits at the intersection of diagnostics, software, and consumer health technology. The Libre Duo 10 Day extends that trend by turning a measurement once handled through spot checks into a continuous digital signal.
That matters commercially because it pushes monitoring platforms toward richer, more clinically specific datasets. Companies are no longer competing only on glucose accuracy, sensor wear time, or app design. They are also looking for adjacent biomarkers that can make wearables more useful in preventing high-cost medical events. DKA is a strong target because it is dangerous, time-sensitive, and expensive when it leads to hospitalization.
There are still practical questions that the authorization alone does not answer. Pricing, reimbursement, patient adherence, and clinician workflow will shape whether the device becomes widely used or remains concentrated among high-risk groups. The supplied source text also does not provide sensitivity, specificity, or false-alert data, all of which will matter in real-world adoption.
Still, the regulatory milestone is clear. The FDA has authorized the first wearable built to continuously track ketones and glucose together. For patients vulnerable to rapid metabolic deterioration, that creates the possibility of moving ketone detection from an occasional manual check to a continuous warning system. In diabetes care, where complications can escalate in hours, that is a meaningful change in capability.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
